(CELU) –
-
Form 8-K Celularity Inc For: Nov 21
-
Celularity (CELU) Receives Nasdaq Notice Regarding Late 10-Q
-
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
-
Form NT 10-Q Celularity Inc For: Sep 30
-
Celularity (CELU) Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification
-
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification
-
Form 4 Celularity Inc For: Aug 31 Filed by: Ling Geoffrey M.D.
-
Form 3 Celularity Inc For: Aug 31 Filed by: Ling Geoffrey M.D.
-
Form 4 Celularity Inc For: Sep 29 Filed by: Hariri Robert J
-
Form SC 13G/A Celularity Inc Filed by: Sorrento Therapeutics, Inc.
-
Form 4 Celularity Inc For: Sep 29 Filed by: Sorrento Therapeutics, Inc.
-
Form 8-K Celularity Inc For: Sep 14
-
Form 8-K Celularity Inc For: Aug 31
-
Celularity (CELU) Appoints Geoffrey Shiu Fei Ling to its Board
-
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
-
Form 8-K Celularity Inc For: Aug 29
-
Celularity (CELU) Announces Multi-Year Research Collaboration Services Agreement With Regeneron
-
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
-
Form 8-K Celularity Inc For: Aug 21
-
Form 10-Q Celularity Inc For: Jun 30
-
Form 8-K Celularity Inc For: Jul 31
-
Form 8-K Celularity Inc For: Jul 27
-
Form 424B5 Celularity Inc
-
Celularity (CELU) Announces $3 Million Registered Direct Offering of Common Stock, Warrants
-
Celularity Inc. Announces $3 Million Registered Direct Offering
-
Celularity (CELU) and Versea Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance 3l Ocular For Ophthalmic Applications
-
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications
-
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.23%
-
Form 4 Celularity Inc For: Jul 14 Filed by: Kilcoyne Adrian
-
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies
-
Form 4/A Celularity Inc For: Jun 14 Filed by: Lim Kok Thay
-
Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics
-
Form SC 13D/A Celularity Inc Filed by: Dragasac Ltd
-
Form 4 Celularity Inc For: Jun 20 Filed by: Genting Berhad
-
Form 8-K Celularity Inc For: Jun 20
-
Form 4 Celularity Inc For: Jun 14 Filed by: Parks Diane L.
-
Form 4 Celularity Inc For: Jun 14 Filed by: Kehler Dean C
-
Form 4 Celularity Inc For: Jun 14 Filed by: VON ESCHENBACH ANDREW C.
-
Form 4 Celularity Inc For: Jun 14 Filed by: Mazur Marc
-
Form 4 Celularity Inc For: Jun 14 Filed by: Smith Robin L
-
Form 4 Celularity Inc For: Jun 14 Filed by: SCULLEY JOHN
-
Form 4 Celularity Inc For: Jun 14 Filed by: Diamandis Peter
-
Form 4 Celularity Inc For: Jun 14 Filed by: Lim Kok Thay
-
Form 8-K Celularity Inc For: Jun 14
-
Form EFFECT Celularity Inc
-
Form 424B3 Celularity Inc
-
Celularity (CELU) Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability
-
Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability
-
Form 8-K Celularity Inc For: May 31
-
Form S-3 Celularity Inc
Back to CELU Stock Lookup
